Pretreatment prostate-specific antigen density as a predictor of biochemical recurrence in patients with prostate cancer: a meta-analysis.

Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Prostate-Specific Antigen* ; Prostatic Neoplasms*/surgery; Male ; Humans ; Prostatectomy ; Consensus ; Databases, Factual

Background: A consensus has not been reached on the value of prostate-specific antigen density (PSAD) as a predictor of biochemical recurrence of prostate cancer. This meta-analysis aimed to evaluate the association between PSAD and biochemical recurrence of prostate cancer after primary treatment.
Methods: Two authors systematically searched PubMed, Web of Science, and Embase databases (up to August September 10, 2023) to identify studies that assessed the value of pretreatment PSAD in predicting biochemical recurrence after primary treatment (radical prostatectomy or radiotherapy) of prostate cancer. A random effect model was used to pool adjusted hazard ratios (HR) with 95% confidence intervals (CI) for biochemical recurrence.
Results: Nine studies with 4963 patients were eligible for the meta-analysis. The reported prevalence of biochemical recurrence ranged from 4 to 55.1%. For patients with higher PSAD compared to those with low PSAD, the pooled HR of biochemical recurrence was 1.59 (95% CI 1.21-2.10). Subgroup analysis showed that the pooled HR of biochemical recurrence was 1.80 (95% CI 1.34-2.42) for patients who received radical prostatectomy, and 0.98 (95% CI 0.66-1.45) for patients who received radiotherapy.
Conclusions: Elevated pretreatment PSAD may be an independent predictor for biochemical recurrence of prostate cancer after radical prostatectomy. Determining PSAD could potentially improve the prediction of biochemical recurrence in patients with prostate cancer.
(© 2024. The Author(s).)

Int J Urol. 2015 Nov;22(11):1029-35. (PMID: 26290306)
J Urol. 2010 Jan;183(1):126-31. (PMID: 19913257)
Biometrics. 1994 Dec;50(4):1088-101. (PMID: 7786990)
J Urol. 1992 Mar;147(3 Pt 2):815-6. (PMID: 1371554)
Br J Radiol. 1998 Aug;71(848):868-71. (PMID: 9828800)
Int J Urol. 2015 Feb;22(2):188-93. (PMID: 25339062)
Cancer Diagn Progn. 2022 Jan 3;2(1):49-54. (PMID: 35400005)
JAMA. 1998 Sep 16;280(11):969-74. (PMID: 9749478)
Urology. 1997 Jul;50(1):73-8. (PMID: 9218022)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
Cancer Manag Res. 2019 Feb 01;11:1133-1139. (PMID: 30774441)
J Urol. 2012 Dec;188(6):2165-70. (PMID: 23083861)
BMC Urol. 2017 Jun 23;17(1):47. (PMID: 28645325)
Eur Urol. 2019 Jun;75(6):967-987. (PMID: 30342843)
Urol Oncol. 2015 Apr;33(4):164.e1-9. (PMID: 25620154)
Oncol Lett. 2023 May 18;26(1):284. (PMID: 37274483)
BMJ. 1997 Sep 13;315(7109):629-34. (PMID: 9310563)
Eur Urol Oncol. 2021 Dec;4(6):877-892. (PMID: 34716119)
Int J Clin Oncol. 2015 Feb;20(1):176-81. (PMID: 24771079)
J Clin Epidemiol. 2009 Oct;62(10):e1-34. (PMID: 19631507)
BJU Int. 2012 Dec;110(11 Pt B):E494-9. (PMID: 22540236)
J Urol. 1995 Jun;153(6):1855-9. (PMID: 7538598)
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-8. (PMID: 35503984)

BK20191221 Provincial Natural Science Foundation Project of Jiangsu of China; BE2016715 Social Development Plan of Jiangsu Province-Standardization of Key Disease Diagnosis and Treatment Project; H2017089 Commission of Health and Family Planning Foundation Jiangsu Provincial of China

Keywords: Biochemical recurrence; Prostate cancer; Prostate-specific antigen density; meta-analysis

EC 3.4.21.77 (Prostate-Specific Antigen)

Date Created: 20240306 Date Completed: 20240308 Latest Revision: 20240309

20240309

PMC10916317

10.1186/s12885-024-12029-8

38448818